v3.26.1
FAIR VALUE - Narrative (Details)
3 Months Ended 12 Months Ended
Sep. 16, 2024
USD ($)
Feb. 22, 2024
USD ($)
Dec. 12, 2023
USD ($)
Mar. 31, 2026
USD ($)
shares
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2023
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Contingent consideration / contingent value rights       $ 8,600,000   $ 8,300,000  
Money market fund       242,196,000   209,891,000  
Interest rate swap       1,513,000   1,646,000  
Unrealized gain (loss) on investment in equity securities       5,753,000 $ (921,000)    
Securities held, value       $ 14,885,000   9,131,000 $ 0
Achievement of milestones payment period       24 months      
CG Oncology              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Shares held (in shares) | shares       219,925      
Investment, cost       $ 67.68   41.52  
Accrued Licensor Payments              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Fair value of payments       14,900,000   9,100,000  
Alimera Sciences, Inc | Contingent Value Rights Agreement              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Contingent consideration classified as equity, fair value disclosure       1,000,000.0   1,400,000  
Increase (decrease) in fair value disclosure       (400,000)      
Alimera Sciences, Inc              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Business combination, milestone payment multiplier 0.25            
Contingent consideration / contingent value rights       1,027,000   $ 1,428,000  
Novitium              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Additional contingent consideration       $ 46,500,000      
Payments on contingent consideration   $ 12,500,000 $ 12,500,000        
Net profit generated by the sales       20.00%      
Maximum net profit generated by sales owed       $ 21,500,000      
Payment period       45 days      
Collaborative arrangement, percentage of net profit generated by sales, quarterly payment due, accrued       $ 100,000 $ 100,000    
2026 Milestone Revenue Payment | Alimera Sciences, Inc              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Revenues $ 140,000,000.0            
Business combination, divisible revenue $ 10,000,000.0            
2027 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Contingent consideration, milestone payment, CVRs agreement business days 15 days            
2027 Milestone Revenue Payment | Alimera Sciences, Inc              
Fair Value Measurement Inputs and Valuation Techniques [Line Items]              
Revenues $ 160,000,000.0            
Business combination, divisible revenue $ 15,000,000.0